The Decline of Pharmaceutical Innovation in Europe
The first keynote speaker Georgette Lalis, Head of DG Enterprise and Industry for the European Commission, began her presentation "The Decline of Pharmaceutical Innovation in Europe" by acknowledging, "Innovation is the life blood of the pharmaceutical industry." She added that regulators must be equally innovative, playing a key role in the growth of R&D development in Europe, noting that Europe is facing massive health threats and the health system is under distress.
The first keynote speaker Georgette Lalis, Head of DG Enterprise and Industry for the European Commission, began her presentation "The Decline of Pharmaceutical Innovation in Europe" by acknowledging, "Innovation is the life blood of the pharmaceutical industry." She added that regulators must be equally innovative and play a key role in the growth of R&D development in Europe, noting that Europe is facing massive health threats and has a health system that is under distress.
Lalis suggested that Europe needs to inject a new impetus and not increase barriers-this will help develop a firm foundation for innovation. And although a great deal has been achieved (such as successful orphan regulation, an increase in the number of new medicines and pediatric medications, and developing legislation for tissue engineering and cell therapy), what has been done so far is still not enough. Lalis added that the Commission will propose a series of measures to remove bureaucratic hurdles and that there needs to be a refocus on non-legislative areas, such as improving information to patients, assessing cost effectiveness of drugs, and looking for alternative approaches to pricing. "Innovation is not new to Europe," she concluded.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
